By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said is seeking approval from the European Medicines Agency for subcutaneous use of Darzalex in patients with multiple myeloma.
Darzalex is currently only approved for intravenous use.
Janssen said subcutaneous Darzalex is co-formulated with Halozyme Therapeutics Enhanze drug-delivery technology.
Janssen last week filed for U.S. Food and Drug Administration approval for the subcutaneous formulation of Darzalex in multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.
Write to Colin Kellaher at firstname.lastname@example.org